IrelandIreland

Label change for Elan's MS-drug permits safer use

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the JC-virus marks a higher risk of developing progressive multifocal leukoencephalopathy (PML). A new label identifies anti-JCV antibody status as a third risk factor for developing PML. Tysabri (natalizumab) increases the risk of PML, an opportunistic viral infection of the brain which in most cases leads to death or severe disability. With the label update, which the companies say was inspired by their own research, physicians now have others factor at hand when weighing the risks and benefits of applying Tysabri. “We welcome the inclusion of PML risk stratification in the U.S. label as it significantly supports our aim to provide the information patients and physicians need to make a more informed treatment decision,” said Kelly Martin, CEO of Elan. Tysabri is approved in about 65 countries and results in a 68% relative reduction in the annualised relapse rate when compared with placebo, according to studies conducted by Elan.

IrelandIreland

26.05.2011

Dublin – Ireland’s Elan Corporation plc has paid US$50m to access Proteostasis Therapeutics’ pipeline of proteostasis regulators, peptidomimetic compounds that regulate protein folding, protein aggregation and protein degradation...

IrelandIreland

06.02.2011

Dublin – Irish drug maker Elan Corp. plc announced it has reduced its headcount by 130 (10%) to about 1,200. Elan said a nearly half of the 130 cuts came from the firm’s R&D department, and primarily occurred at its site in San...

IrelandIreland

07.09.2010

Nottingham/Dublin – Irish researchers have identified a new target in S.aureus bacteria that cause progressive bone destruction. According to Tania Claro from Royal College of Surgeons, S. aureus makes use of its surface protein...

IrelandIreland

11.08.2010

Elan Corporation plans to advance ELND005 into phase III testing, despite data indicating that it missed the co-primary endpoints in a phase II AD201 trial for Alzheimer's. According to the trial results, ELND005, a small...

IrelandIreland

03.08.2010

Dublin/St. Paul – Irish researchers have reported that a specific gene variant may increase the severity of multiple sclerosis (MS) symptoms. For the study, which was published in Neurology (3rd August), the research team led by...

IrelandIreland

20.04.2010

Dublin – Irish neuroscience specialist Elan Corporation plc has announced it is investigating the option of spinning out its Elan Drug Technologies business, creating two publicly listed enterprises. Elan is currently assessing...

IrelandIreland

02.03.2010

Dublin – The Elan Corporation has established a novel biomarker, 11C-PiB PET, that can detect whether Alzheimer drug candidates can reduce pathogenic beta-amyloid plaques in the brains of patients. With the new marker, Elan...

IrelandIreland

17.12.2009

Dublin – Irish company Elan Corporation plc and its partner Transition Therapeutics have withdrawn patients from two ongoing phase II trials with the compound ELDN005 following the death of nine patients. The studies were stopped...

Displaying results 11 to 20 out of 49

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/1/article/label-change-for-elans-ms-drug-permits-safer-use.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR32.3%
  • ADDEX3.44 CHF7.8%
  • HBM86.00 CHF4.4%

FLOP

  • PAION2.19 EUR-32.8%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-25.0%

TOP

  • SANTHERA82.00 CHF2184.1%
  • CO.DON2.82 EUR200.0%
  • PAION2.19 EUR157.6%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 22.10.2014


Current issue

All issues

Product of the week

Products